Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees University PennsylvaniafiledCriticalTrustees University Pennsylvania
Publication of ECSP099393ApublicationCriticalpatent/ECSP099393A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La invención se relaciona con compuestos radiomarcados y su uso en métodos para el diagnóstico por imágenes de depósitos amiloides, y métodos para su fabricación. La invención se relaciona también con compuestos para inhibir la agregación de las proteínas amiloides que forman los depósitos amiloides, métodos para administrar agentes terapéuticos en depósitos amiloides y métodos para preparar compuestos que inhiben la agregación de proteínas amiloides.The invention relates to radiolabelled compounds and their use in methods for diagnostic imaging of amyloid deposits, and methods for their manufacture. The invention also relates to compounds for inhibiting the aggregation of amyloid proteins that form amyloid deposits, methods for administering therapeutic agents in amyloid deposits and methods for preparing compounds that inhibit aggregation of amyloid proteins.
ECSP0993932006-12-062009-06-08
DERIVATIVES OF ACETYLENE AND ITS USE FOR THE UNION TO AMILOID PLATES AND ITS DIAGNOSIS BY IMAGES
ECSP099393A
(en)
The use of s1p receptor modulating or agonist compounds to decrease heart rate by approximately 2 beats / minute; method to reduce, prevent or limit a negative chronotropic effect; a pharmaceutical kit
compound, pharmaceutical composition, methods for inhibiting tau aggregation in a mammal and for evaluating tau deposits in a patient, and use of a compound.
Compounds derived from amino-pyrimidines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others.
Compounds derived from amino-pyridazines; pharmaceutical compositions comprising them; and its use for the treatment of a disease selected condition of neuromuscular disorders, amyotrophic lateral sclerosis, myasthenia gravis, among others.
compound for inhibiting the aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases and in aggregated protein imaging deposits, use thereof, and kit
compound, pharmaceutical composition, use of a compound, and methods of imaging a human or animal body by optical imaging, and monitoring the effect of treating a human or animal body with a drug to combat a condition associated with angiogenesis
Compounds derived from imidazo [1,2-a] pyridine-2-heterocyclyl-methanone, modulators of nuclear receptors nurr1; intermediate compounds; pharmaceutical composition; medicine; and use for the treatment and prevention of neurodegenerative, psychiatric, inflammatory diseases, osteoporosis, cancer, among others.
Compounds derived from l-glutamic acid labeled with [f-18] and derivatives of l-glutamine labeled with [f-18]; preparation procedure; image diagnosis set; pharmaceutical compositions; and use for imaging of tumor diseases.